{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:22:15Z","timestamp":1792686135618,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jemermed.2025.07.022","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T11:13:59Z","timestamp":1751973239000},"page":"288-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comparative Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Cancer Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4976-7814","authenticated-orcid":false,"given":"Mohammed Maan","family":"Al-Salihi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Sabah","family":"Al-Jebur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abd","family":"Elazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Shing","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan I.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2025.07.022_bib0001","first-page":"195","article-title":"Atrial fibrillation: the current epidemic","volume":"14","author":"Morillo","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/20009666.2019.1593781","article-title":"Stroke risk stratification in atrial fibrillation: a review of common risk factors","volume":"9","author":"Oladiran","year":"2019","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.mad.2017.05.002","article-title":"Cancer-incidence, prevalence and mortality in the oldest-old. A comprehensive review","volume":"164","author":"Nolen","year":"2017","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/1472-6963-14-329","article-title":"Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis","volume":"14","author":"Lang","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0005","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamainternmed.2017.5512","article-title":"Association of Warfarin use with lower overall cancer incidence among patients older than 50 years","volume":"177","author":"Haaland","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0006","first-page":"531","article-title":"Choosing non-vitamin K antagonist oral anticoagulants: practical considerations we need to know","volume":"16","author":"Amin","year":"2016","journal-title":"Ochsner J"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/suab153","article-title":"The value and limitations of new oral anticoagulant plasma level assessments","volume":"24","author":"Van der Linden","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0008","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF","volume":"5","author":"Chen","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100096","article-title":"Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice","volume":"7","author":"Chu","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.neo.7900263","article-title":"The hypercoagulable state of malignancy: pathogenesis and current debate","volume":"4","author":"Caine","year":"2002","journal-title":"Neoplasia"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0011","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with cancer: JACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0012","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4103\/0971-3026.169459","article-title":"Beyond warfarin: the advent of new oral anticoagulants","volume":"25","author":"Laroia","year":"2015","journal-title":"Indian J Radiol Imaging"},{"key":"10.1016\/j.jemermed.2025.07.022_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jemermed.2025.07.022_bib45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0013","first-page":"Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0014","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0015","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing The Quality of Nonrandomised Studies in Meta-analyses","first-page":"7","author":"Wells","year":"2014"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0016","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0017","doi-asserted-by":"crossref","first-page":"10937","DOI":"10.1038\/s41598-023-38071-3","article-title":"Impact of type of anticoagulant on clinical outcomes in cancer patients who had atrial fibrillation","volume":"13","author":"Chai-Adisaksopha","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaccao.2021.06.004","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer","volume":"3","author":"Deitelzweig","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0020","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4070\/kcj.2017.0328","article-title":"Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer","volume":"48","author":"Kim","year":"2018","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.122.008951","article-title":"Comparative effectiveness and safety of direct oral anticoagulants versus Warfarin among adults with cancer and atrial fibrillation","volume":"15","author":"Mehta","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0022","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus Warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0023","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cam4.1054","article-title":"Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study","volume":"6","author":"Ording","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0024","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.breast.2019.05.017","article-title":"Current status of anticoagulation in patients with breast cancer and atrial fibrillation","volume":"46","author":"Pardo Sanz","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jaccao.2022.07.004","article-title":"Outcomes by class of anticoagulant use for nonvalvular atrial fibrillation in patients with active cancer","volume":"4","author":"Potter","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0026","first-page":"706","article-title":"Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study","volume":"16","author":"Sawant","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0027","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0028","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7150\/jca.36468","article-title":"Novel oral anticoagulant versus Warfarin in cancer patients with atrial fibrillation: an 8-year population-based cohort study","volume":"11","author":"Wu","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0029","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2169\/internalmedicine.2415-18","article-title":"Oral anticoagulants in Japanese patients with atrial fibrillation and active cancer","volume":"58","author":"Yasui","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.jemermed.2025.07.022_bib43","doi-asserted-by":"crossref","first-page":"20230430","DOI":"10.3390\/cancers15092574","article-title":"Systematic review and meta-analysis of oral anticoagulant therapy in atrial fibrillation cancer patients","volume":"15","author":"Cereda","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jemermed.2025.07.022_bib48","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2459\/JCM.0000000000001041","article-title":"Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis","volume":"21","author":"Casula","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.jemermed.2025.07.022_bib0030","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2025.07.022_bib40","article-title":"Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants","volume":"126","author":"Jaffer","year":"2016","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jemermed.2025.07.022_bib46","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2025.07.022_bib47","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2025.07.022_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0006-2952(88)90750-2","article-title":"Warfarin: metabolism and mode of action","volume":"37","author":"Park","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jemermed.2025.07.022_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40560-016-0144-5","article-title":"Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences","volume":"4","author":"Ieko","year":"2016","journal-title":"J Intensive Care"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467925002756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467925002756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T03:25:02Z","timestamp":1764473102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467925002756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"alternative-id":["S0736467925002756"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2025.07.022","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Cancer Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2025.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}